CYTK stock forecast, quote, news & analysis
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more
Cytokinetics (CYTK) Stock Analysis: MYQORZO Launch Gains Traction as Pipeline Catalysts Pile Up
Key Takeaways
- Cytokinetics shares traded near $80.63 as of late July 2026, reflecting a modest pullback of roughly 2% over the prior 30 days amid broader biotech consolidation.
- The company's first commercial product, MYQORZO (aficamten), generated $4.8 million in net U.S. sales during its initial nine weeks on the market, surpassing internal expectations.
- The pivotal Phase 3 ACACIA-HCM trial met both primary endpoints in non-obstructive HCM, potentially doubling the drug's addressable patient population.
- Analyst consensus remains a Moderate Buy with an average price target around $99.90, implying meaningful upside from current levels.
- Upcoming Q2 2026 earnings and the FDA's November PDUFA date for the MAPLE-HCM label expansion represent near-term catalysts.
Current Market Snapshot
Cytokinetics (CYTK) traded near $80.63 in late July 2026, holding within a relatively tight range over the prior month following the stock's sharp rally earlier in the year. The 50-day simple moving average sat near $77.99 and the 200-day moving average around $69.10, indicating that the stock remained above both key technical levels. With a market capitalization of approximately $10 billion, CYTK has transitioned from a clinical-stage biotech into a commercial-stage specialty cardiovascular company. The 12-month range of $32.89 to $88.31 underscores the magnitude of the repricing that accompanied the FDA approval and launch of MYQORZO.
Cytokinetics (CYTK) Business Overview and Competitive Position
Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of expertise in muscle biology. Its lead asset, MYQORZO (aficamten), is a cardiac myosin inhibitor approved in the U.S., Europe, and China for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The drug works by reducing excessive cardiac contractility, thereby alleviating left ventricular outflow tract obstruction. Cytokinetics also advances a broader pipeline including omecamtiv mecarbil, a cardiac myosin activator in Phase 3 for heart failure with severely reduced ejection fraction, and ulacamten, a cardiac myosin inhibitor in Phase 2 for heart failure with preserved ejection fraction. The company competes primarily with Bristol Myers Squibb's (BMY) Camzyos in the cardiac myosin inhibitor space, though MYQORZO's differentiated label, flexible REMS program, and absence of drug-drug interaction consultation requirements have been cited by prescribers as competitive advantages.
Recent Developments Driving CYTK
The most consequential event of the past several months was the positive topline readout from ACACIA-HCM, the pivotal Phase 3 trial evaluating aficamten in patients with symptomatic non-obstructive HCM. Announced alongside Q1 2026 earnings on May 5, the trial met both dual primary endpoints with statistically significant improvements in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and peak VO2 versus placebo. No new safety signals emerged. These results open a path toward label expansion into nHCM, a patient population that currently has no approved pharmacologic therapy. Management has indicated plans to discuss the data with the FDA and other regulators for a potential supplemental New Drug Application.
On the commercial front, MYQORZO's U.S. launch exceeded early benchmarks. By the end of Q1 2026, over 275 healthcare providers had prescribed the drug to approximately 680 patients, with more than 70% of those on therapy converting to paid prescriptions. By April, prescriber counts grew beyond 425 and patient numbers climbed to roughly 1,100. The first European launch commenced in Germany during Q2 2026, extending the drug's commercial footprint. Meanwhile, the FDA accepted the supplemental NDA for MAPLE-HCM, which evaluated aficamten as monotherapy versus metoprolol, assigning a PDUFA target action date of November 14, 2026.
Institutional activity remained constructive, with Vanguard, State Street, Deep Track Capital, and Principal Financial Group all adding to their positions during recent quarters. On the analyst side, Mizuho raised its price target to $118 while maintaining an Outperform rating, Morgan Stanley lifted its target to $103 with an Overweight rating, and HC Wainwright set a Street-high target of $140. Insider selling by the CEO and EVP was conducted under pre-arranged Rule 10b5-1 trading plans and represented small fractions of their total holdings. The company ended Q1 2026 with approximately $1.1 billion in cash and investments, providing a multi-year runway to fund commercialization and pipeline advancement.
Trending AI Robots
For investors seeking data-driven approaches to navigate stocks like Cytokinetics, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers across diverse strategies and timeframes, but only the most relevant and consistently high-performing bots are featured in this dynamically updated section. These bots vary in methodology — from swing trading and trend following to pattern recognition and momentum-based strategies — allowing traders to explore approaches aligned with their risk tolerance and objectives. Monitoring which AI-driven strategies are gaining traction can offer an additional perspective on evolving market dynamics.
2026 Outlook and What Investors Should Watch
The second half of 2026 presents a dense calendar of milestones for Cytokinetics. The Q2 2026 earnings report, expected around early August, will provide the first full-quarter look at MYQORZO's U.S. sales trajectory and initial revenue contributions from the German launch. The FDA's decision on the MAPLE-HCM sNDA, with a PDUFA date of November 14, 2026, could add monotherapy data to the MYQORZO label and strengthen competitive positioning against Camzyos. Regulatory discussions around the ACACIA-HCM results will clarify the timeline for a potential nHCM indication — a catalyst that analysts view as transformative given the absence of approved therapies for that population. Additional pipeline updates are expected, including continued enrollment in the COMET-HF Phase 3 trial of omecamtiv mecarbil and completion of Cohort 1 enrollment in the AMBER-HFpEF Phase 2 study of ulacamten. Investors should also monitor payer dynamics, as commercial insurance coverage expansion is anticipated through the second half of 2026. Competitive developments from BMY, including the FDA's September 2026 PDUFA date for Camzyos in adolescent oHCM, may influence sentiment around the HCM treatment landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CYTK in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 31, 2026
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 43 cases where CYTK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CYTK moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at .
CYTK moved below its 50-day moving average on July 31, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CYTK entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (88.496) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in discovery and development of small molecule drug therapeutics
Industry Biotechnology